Calico_M20-405

Summary

To assess the safety, tolerability, and pharmacokinetics (PK) of A-1684909 following multiple doses of ABBV-CLS-7262 (A-1684909 prodrug) in subjects with amyotrophic lateral sclerosis (ALS).


Inclusion Criteria

  • Must have an identified, reliable caregiver
  • Confirmed diagnosis of Familial ALS or Sporadic ALS
  • First ALS symptoms occurred ≤36 months before screening
  • Able to swallow solids
Show more

Study Location(s)

Beverly

More about this Clinical Trial

Full Title

A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of ABBV-CLS-7262 in Subjects with Amyotrophic Lateral Sclerosis Followed by an Active Treatment Extension

Details
Disease Type/Condition

ALS

Principal Investigator

Diaz, Frank

Age Group

Adult

Phase

I

IRB Number

STUDY00001802

ClinicalTrials.gov ID

NCT04948645

Key Eligibility
ClinicalTrials.gov

Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

ALS

Principal Investigator

Diaz, Frank

Age Group

Adult

Phase

I

IRB Number

M20-405

ClinicalTrials.gov ID

NCT04948645

Key Eligibility
ClinicalTrials.gov

Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?